Accession Number:

ADA415595

Title:

Targeting Breast Cancer Vasculature

Descriptive Note:

Annual rept. 1 Mar 2002-28 Feb 2003

Corporate Author:

BURNHAM INST LA JOLLA CA

Personal Author(s):

Report Date:

2003-03-01

Pagination or Media Count:

21.0

Abstract:

The main problems with current cancer therapies, including those for breast cancer, are that they are only partially effective and highly toxic. We work on a strategy that enhances the efficacy of anti-tumor therapies, while simultaneously decreasing the side effects. Our target is the vasculature of tumors. Tumor cells depend on blood supply and the tumor vasculature is accessible through the blood stream. An added advantage is that the vasculature is composed of normal cells, which are unlikely to develop resistance to treatments. We identify tumor-specific vascular markers by screening phage-displayed peptide libraries in mice bearing breast cancer xenografts or endogenous transgenic breast cancers. When the libraries are intravenously injected into the mice, the phage that have specific affinity for tumor vasculature home to the tumors. These peptides can then be used to carry drugs and other therapeutics into tumors. During the past year, we have identified a a tumor-homing peptide that binds to a collagen that is over-expressed in breast cancer vasculature and b peptides that home to lymphatic vessels in tumors. The homing peptides that target tumor lymphatics represent an important extension of the vascular targeting technology. Destroying the lymphatics and tumor cells in and around them with targeted drugs may be particularly useful in preventing metastasis.

Subject Categories:

  • Medicine and Medical Research
  • Toxicology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE